(Q38392935)

2 September 2017

EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer (English)

1 reference

2 September 2017

9

David Klimstra

1 reference

2 September 2017

Christiane Daniela Fichter

1

1 reference

2 September 2017

Sylvia Timme

2

1 reference

2 September 2017

Julia Alexandra Braun

3

1 reference

2 September 2017

Verena Gudernatsch

4

1 reference

2 September 2017

Anja Schöpflin

5

1 reference

2 September 2017

Lioudmilla Bogatyreva

6

1 reference

2 September 2017

Helene Geddert

7

1 reference

2 September 2017

Gerhard Faller

8

1 reference

2 September 2017

Laura Tang

10

1 reference

2 September 2017

Dieter Hauschke

11

1 reference

2 September 2017

Martin Werner

12

1 reference

2 September 2017

Silke Lassmann

13

1 reference

2 September 2017

language of work or name

English

0 references

publication date

2 April 2014

1 reference

International Journal of Cancer

2 September 2017

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

2 September 2017

135

1 reference

2 September 2017

7

1 reference

2 September 2017

1517-1530

1 reference

Untangling the ErbB signalling network

2 September 2017

1 reference

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

21 January 2018

Oesophageal carcinoma

1 reference

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas

21 January 2018

1 reference

Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin

21 January 2018

1 reference

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

21 January 2018

1 reference

Targeting the human EGFR family in esophagogastric cancer

21 January 2018

1 reference

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE).

21 January 2018

1 reference

Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.

21 January 2018

1 reference

HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma

21 January 2018

1 reference

Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer

21 January 2018

1 reference

Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo

21 January 2018

1 reference

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines

21 January 2018

1 reference

Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.

21 January 2018

1 reference

Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma

21 January 2018

1 reference

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

21 January 2018

1 reference

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

21 January 2018

1 reference

Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

21 January 2018

1 reference

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

21 January 2018

1 reference

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review

21 January 2018

1 reference

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models

21 January 2018

1 reference

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells

21 January 2018

1 reference

In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer

21 January 2018

1 reference

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action

21 January 2018

1 reference

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers

21 January 2018

1 reference

Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.

21 January 2018

1 reference

Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells

21 January 2018

1 reference

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

21 January 2018

1 reference

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

21 January 2018

1 reference

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

21 January 2018

1 reference

A systematic approach to therapeutic target selection in oesophago-gastric cancer

21 January 2018

1 reference

Resistance to Trastuzumab in Breast Cancer.

21 January 2018

1 reference

Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer

21 January 2018

1 reference

Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28771

1 reference

2 September 2017

1 reference